Literature DB >> 11168009

Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE).

M Bijl1, G Horst, P C Limburg, C G Kallenberg.   

Abstract

Disturbances in apoptosis or in the clearance of apoptotic material might result in increased presentation of autoantigens which could be relevant to the pathogenesis of SLE. Data concerning defects in apoptosis in SLE are conflicting. To determine whether intrinsic defects in apoptosis induction occur in SLE irrespective of disease activity, we examined anti-CD3 and anti-Fas-induced apoptosis in vitro in SLE patients with inactive disease. Isolated peripheral blood lymphocytes (PBL) from 13 SLE patients and 14 healthy controls were incubated with anti-CD3, and, subsequently, after up-regulation of membrane Fas following anti-CD3 incubation, with anti-Fas. Expression of Fas and levels of apoptosis as detected by annexin V and propidium iodide staining were assessed by flow cytometry before and after the respective incubations. Fas expression on freshly isolated lymphocytes of SLE patients was increased whereas levels of circulating apoptotic cells were comparable between patients and controls. Stimulation with anti-CD3 resulted in up-regulation of membrane Fas in patients and in controls. In vitro induction of apoptosis by anti-CD3 as well as by anti-Fas occurred both in SLE patients and controls, and was higher in SLE patients after incubation with anti-CD3 as well as with anti-Fas. We conclude that Fas expression and in vitro induction of apoptosis are increased in SLE even in the absence of disease activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168009      PMCID: PMC1905956          DOI: 10.1046/j.1365-2249.2001.01418.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.

Authors:  T Miyawaki; T Uehara; R Nibu; T Tsuji; A Yachie; S Yonehara; N Taniguchi
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

2.  Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response?

Authors:  P E Spronk; E J ter Borg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

4.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

Authors:  I Nicoletti; G Migliorati; M C Pagliacci; F Grignani; C Riccardi
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

5.  Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity.

Authors:  P A Courtney; A D Crockard; K Williamson; J McConnell; R J Kennedy; A L Bell
Journal:  Lupus       Date:  1999       Impact factor: 2.911

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

8.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

9.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.

Authors:  J Cheng; T Zhou; C Liu; J P Shapiro; M J Brauer; M C Kiefer; P J Barr; J D Mountz
Journal:  Science       Date:  1994-03-25       Impact factor: 47.728

10.  The apoptosis-1/Fas protein in human systemic lupus erythematosus.

Authors:  E Mysler; P Bini; J Drappa; P Ramos; S M Friedman; P H Krammer; K B Elkon
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  5 in total

1.  The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus.

Authors:  Maryam Rastin; Mohammad Reza Hatef; Nafisseh Tabasi; Mahmoud Mahmoudi
Journal:  Clin Rheumatol       Date:  2011-08-12       Impact factor: 2.980

2.  Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain.

Authors:  Dirk Langnickel; Philipp Enghard; Claudia Klein; Reinmar Undeutsch; Berthold Hocher; R Manz; G R Burmester; Gabriela Riemekasten
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

3.  Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.

Authors:  M N Lub-de Hooge; E G E de Vries; S de Jong; M Bijl
Journal:  Ann Rheum Dis       Date:  2004-11-25       Impact factor: 19.103

4.  Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis.

Authors:  Lian-Hong Li; Wen-Xian Li; Ou Wu; Guo-Qing Zhang; Hai-Feng Pan; Xiang-Pei Li; Jian-Hua Xu; Hong Dai; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2008-11-20       Impact factor: 2.316

5.  T lymphocyte apoptosis in systemic lupus erythematosus patients.

Authors:  Maryam Rastin; Mahmoud Mahmoudi; Mohammadreza Hatef; Maryam Sahebari; Nafiseh Tabasi; Dariush Haghmorad; Reza Nosratabadi; Shahrzad Zamani; Mahdieh Khazaee; Mitra Masoudian
Journal:  Iran J Basic Med Sci       Date:  2013-08       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.